In this exploratory study, we identified SNPs in regulatory regions of SLC22A4 and SLC22A5 genes, coding imatinib transporters, which were significantly associated with outcome of imatinib in CML patients. The gene discussed is SLC22A4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.